Carcinomas in situ were absent from Cys557Ser carriers, whereas they were present at a frequency 12% in non-carriers (age-adjustedp < 0.001), suggesting more aggressiveness of BARD1 variant tumors. Here, BARD1 is linked to in situ carcinoma.